Recently, Merck (MRK) released a positive update from one of its phase 3 lung cancer studies known as KEYNOTE-407. This new update will help it to expand its label for treating front-line lung cancer patients using its drug Keytruda. This means Merck pretty much has a handle on the majority of the front-line lung cancer market, and that is very bullish. For that reason, I believe that Merck is a good buy.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
